524470 — Syncom Formulations (India) Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapHigh Flyer

Annual income statement for Syncom Formulations (India), fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st	2026 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	IAS	IAS	IAS	IAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	2,197	2,243	2,634	4,650	4,892
Cost of Revenue
Gross Profit	791	776	1,008	1,525	2,049
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	2,041	2,055	2,342	4,120	4,182
Operating Profit	155	187	292	530	709
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	262	266	340	655	1,011
Provision for Income Taxes
Net Income After Taxes	198	201	253	494	764
Net Income Before Extraordinary Items
Net Income	198	201	253	494	764
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	198	201	253	494	764
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.226	0.227	0.283	0.54	0.81
Dividends per Share